A recent study explored the efficacy of agenT-797, an allogeneic, unmodified invariant natural killer T cell therapy that was originally developed for use in cancer. The invariant natural killer T cell therapy demonstrated the capability to rejuvenate exhausted T cells, initiate an anti-inflammatory cytokine response, and potentially enhance anti-viral immunity, which will help combat infections and alleviate severe lung inflammation. The open-labeled trial involved 20 mechanically ventilated patients with severe acute respiratory distress syndrome resulting from COVID-19.
Among the participants, 70% survived at the 30-day mark, compared to a 10% survival rate in the control group. Notably, those who received the highest dosage of agenT-797 experienced an 80% reduction in bacterial pneumonia infection compared to lower dosage recipients. Five patients on veno-venous extracorporeal…
